| 引用本文:关荣1，程纬1，杜江2，吴治龙1.参一胶囊在晚期非小细胞肺癌维持治疗中的疗效观察[J].世界中医药,2016,(04):. |
|
| 参一胶囊在晚期非小细胞肺癌维持治疗中的疗效观察 |
| The effect of Shenyi Capsule on the Maintaining Therapeutic Treatment of Advanced Non Small Cell Lung Cancer |
| 投稿时间：2016-03-20 |
| DOI：10.3969/j.issn.1673-7202.2016.04.014 |
| 中文关键词: 非小细胞肺癌 晚期 参一胶囊 疗效 |
| English Keywords:Non small cell lung cancer Advanced cancer Shenyi capsule Curative effect |
| 基金项目: |
|
| 摘要点击次数: 673 |
| 全文下载次数: 905 |
| 中文摘要: |
| 目的：探讨参一胶囊对晚期非小细胞肺癌（NSCLC）的维持治疗效果。方法：选取2012年2月至2014年6月收治的Ⅲb-Ⅳ期NSCLC患者62例作为研究对象，患者均经紫杉醇联合顺铂的一线化疗方案治疗后无疾病进展。按照随机数字表法将62例患者分为对照组30例和观察组32例，分别予对照组以培美曲塞治疗，而观察组接受参一胶囊维持治疗。比较2组治疗2个周期后的临床有效率、临床收益率、生活质量改善情况、免疫功能及不良反应，以及患者预后。结果：治疗2个周期后，观察组治疗总有效率及临床受益率均优于对照组（χ2=5.489、6.441，P<0.05）；观察组生活质量、细胞免疫学指标的改善均优于对照组（P<0.05）；两个组均未见明显不良反应。截至本研究随访时，平均随访时间（35±6.5）m，随访率91.9%。2组1年、2年生存率的比较差异无统计学意义（P>0.05）。结论：参一胶囊作为晚期NSCLC的维持治疗方案，可提高患者的近期临床受益率，改善患者的生存质量，提高患者的机体免疫力，且具有较好的安全性，值得临床推广应用。 |
| English Summary: |
| To investigate the effect of Shenyi capsule on maintaining therapeutic treatment of advanced non small cell lung cancer (NSCLC).Methods:Total 62 patients with stage Ⅲ b~Ⅳ NSCLC in our hospital from 2012 February to 2014 June were chosen to study the effect of paclitaxel combined with cisplatin treatment without progression free first-line chemotherapy. They were randomly divided into control group(n=30) and observation group(n=32) by the random number table method. The control group received pemetrexed for the treatment and the observation group received Shenyi capsule maintenance treatment respectively. The effective rate and clinical benefit rate, immune function, improvement of life quality, adverse reaction and the prognosis of the patients after two courses’ treatment in the two groups were all compared.Results:After two courses’ treatment, the total effective rate and clinical benefit rate of the observation group were better than those of the control group（χ2=5.489、6.441，P<0.05). The improvement of life quality and the cellular immunological indexes of the observation group after the treatment were all higher than those of the control group（P<0.05). And no obvious adverse reactions were found in the two groups. By the end of the follow-up in this study, the average follow-up time was (35±6.5) m, the follow-up rate was 91.9%. There were no statistically significant differences in the survival rates of 1 or 2 year’s survival rate in the two group (P>0.05).Conclusion:Shenyi capsule, as a treatment for advanced NSCLC, can improve the short-term benefit rate, the quality of life and the immunity of NSCLC patients with good security, which is applicable for clinical promotion. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
